Citadel Advisors
PEAR

Citadel Advisors’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Citadel Advisors’s Portfolio PEAR Stock Details PEAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-116,701
Closed -$589K – 14616
2022
Q1 		$589K Buy
+116,701
New +$530K ﹤0.01% 8998
2021
Q4 		– Sell
-1,967,118
Closed -$19.6M – 15171
2021
Q3 		$19.6M Buy
1,967,118
+251,202
+15% +$2.48M ﹤0.01% 2027
2021
Q2 		$17M Buy
1,715,916
+1,000,021
+140% +$9.81M ﹤0.01% 2290
2021
Q1 		$6.87M Buy
+715,895
New +$6.92M ﹤0.01% 3625

Other funds holding PEAR

Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SGA
SB Global Advisers London, United Kingdom $861M AUM 71.72% 1-Year Est. Return
AV
Arboretum Ventures Ann Arbor, Michigan $1.72M AUM 82.7% 1-Year Est. Return
TAA
TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PT
Palantir Technologies Denver, Colorado $9.72M AUM 6.46% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors's PEAR Position: Q2 2022 in Review

Citadel Advisors sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q2 2022, closing a stake of 116,701 shares — an estimated $589K sold.

Citadel Advisors first reported a position in PEAR in Q1 2021 and held it in 4 quarters. The position peaked at $19.6M in Q3 2021. 40 funds tracked by Wall St. Rank hold PEAR as of Q2 2022.

  • Citadel Advisors reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q2 2022 after selling out during the quarter.
  • Citadel Advisors sold 116,701 Pear Therapeutics, Inc. Class A Common Stock shares in Q2 2022, an estimated $589K.
  • Citadel Advisors first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q1 2021 and held it in 4 quarters.
  • Citadel Advisors's Pear Therapeutics, Inc. Class A Common Stock position peaked at $19.6M in Q3 2021.
  • 40 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q2 2022.

Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.